Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek

Completed

• Conditions: Crohn Disease; Inflammatory Bowel Diseases; Colitis, Ulcerative

• Registration Number: NCT05504915
• Lead Sponsor: Osijek University Hospital

Brief Summary

Inflammatory bowel disease consists of ulcerative colitis (UC) or Crohn's disease (CD). The main aim of this study is to describe real-world data on vedolizumab serum concentration and treatment outcomes in cohort of patients treated at the Department of Gastroenterology and Hepatology of University Hospital Center Osijek. Study will be recruiting patients who switched from intravenous to subcutaneous vedolizumab according to routine clinical practice.

Detailed Description

This is a non-interventional, prospective study of participants with IBD who switched from intravenous to subcutaneous vedolizumab in the real world setting.

The study will enroll approximately 30 participants. The data will be collected at the Department of Gastroenterology and Hepatology of University Hospital Center Osijek. All the participants will be assigned to a single observational cohort. All procedures (e.g., blood draw for serum trough concentration of vedolizumab, stool collection for fecal calprotectin or colonoscopy) will be done for routine clinical care. Data will be collected at baseline and at 6-12 months after switch from intravenous to subcutaneous vedolizumab. At baseline, data on age, gender, body mass, diagnosis, time from diagnosis, prior and concomitant therapy for IBD, comorbidities, time from switch from vedolizumab IV to vedolizumab SC, and vedolizumab serum trough concentration during vedolizumab IV therapy, will be collected. At control visit, data on concomitant therapy, adverse events, hospitalization, surgery and vedolizumab serum trough concentration during vedolizumab SC therapy, will be collected. For evaluation of disease remission at baseline and at control visit, Harvey-Bradshaw index (HBI) for Crohn's disease and Partial Mayo score (PMS) for ulcerative colitis (HBI \<5 or PMS \<2); or value of fecal calprotectin (\<150 µ/g); or Simple Endoscopic Score for Crohn's disease (SES-CD) and Mayo endoscopic subscore (MES) for ulcerative colitis (SES-CD \<3 or MES \<2), will be used.

Study Timeline

• Study Start: 2022-05-01
• Study First Submitted: 2022-08-15
• Study First Submitted QC: 2022-08-15
• Study First Posted: 2022-08-17
• Primary Completion: 2023-05-31
• Study Completion: 2023-05-31
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-31
• Last Update Posted: 2023-11-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1. 18 years and older
2. Diagnosis of IBD (UC or CD)
3. Signed informed consent
4. Switched to or planning to switch from vedolizumab IV to vedolizumab SC
5. Disease remission at the time of switch (according to clinical, laboratory or endoscopic parameters)

Exclusion Criteria

1. Corticosteroid therapy at time of switch from vedolizumab IV to vedolizumab SC

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of Surgery After Switching to Vedolizumab SC	Up to 12 months from switch	Surgery due to inflammatory bowel disease activity or complications will be taken into account.
Rate of Treatment Change After Switching to Vedolizumab SC	Up to 12 months from switch	Treatment change is defined as start of corticosteroid therapy, switch to vedolizumab IV again or switch to another biologic or small molecule.
Rate of Hospitalizations After Switching to Vedolizumab SC	Up to 12 months from switch	Hospitalizations due to inflammatory bowel disease activity or complications will be taken into account.
Change in Mean Serum Vedolizumab Through Concentration After Switching from Vedolizumab IV to Vedolizumab SC	Up to 12 months from switch
Percentage of Participants in Remission After Switching to Vedolizumab SC	Up to 12 months from switch	Remission status will be defined by clinical scores (Harvey-Bradshaw index \<5 or Partial Mayo score \<2), by fecal calprotectin (\< 150 mcg/g; if done) or by endoscopic score (SES-CD\<3 or Mayo endoscopic subscore\<2; if done).

Trial Locations

Locations (1)

Klinički bolnički centar Osijek (University Hospital Center Osijek); 🇭🇷 Osijek, Croatia